References
- LohrJM, OliverMR, FrulloniL. Synopsis of recent guidelines on pancreatic exocrine insufficiency. United European Gastroenterol J. 2013;1(2):79–83. doi:10.1177/2050640613476500
- KuhnRJ, EytingS, HennigesF, PotthoffA. In vitro comparison of physical parameters, enzyme activity, acid resistance, and pH dissolution characteristics of enteric-coated pancreatic enzyme preparations: implications for clinical variability and pharmacy substitution. J Pediatr Pharmacol Ther. 2007;12(2):115–128.23055848
- FiekerA, PhilpottJ, ArmandM. Enzyme replacement therapy for pancreatic insufficiency: present and future. Clin Exp Gastroenterol. 2011;4:55–73.21753892
- BrennanGT, SaifMW. Pancreatic enzyme replacement therapy: a Concise Review. JOP. 2019;20(5):121–125.
- NHS UHoL. Pancreatic Enzyme Replacement Therapy (PERT) UHL Guideline B10 2019. Available from: https://secure.library.leicestershospitals.nhs.uk/PAGL/Shared%20Documents/Pancreatic%20Enzyme%20Replacement%20Therapy%20(PERT)%20UHL%20Guideline.pdf. Accessed on 02 Sep 2021.
- ShandroBM, NagarajahR, PoullisA. Challenges in the management of pancreatic exocrine insufficiency. World J Gastrointest Pharmacol Ther. 2018;9(5):39–46. doi:10.4292/wjgpt.v9.i5.3930397535
- LohrJM, HummelFM, PirilisKT, SteinkampG, KornerA, HennigesF. Properties of different pancreatin preparations used in pancreatic exocrine insufficiency. Eur J Gastroenterol Hepatol. 2009;21(9):1024–1031. doi:10.1097/MEG.0b013e328328f41419352190
- MaevIV, KucheryavyyYA, GubergritsNB, et al. Differences in in vitro properties of pancreatin preparations for pancreatic exocrine insufficiency as marketed in Russia and CIS. Drugs R D. 2020;20(4):369–376. doi:10.1007/s40268-020-00326-z33211277
- LohrJM, Dominguez-MunozE, RosendahlJ, et al. United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United European Gastroenterol J. 2017;5(2):153–199. doi:10.1177/2050640616684695
- Dominguez-MunozJE. Pancreatic enzyme therapy for pancreatic exocrine insufficiency. Curr Gastroenterol Rep. 2007;9(2):116–122. doi:10.1007/s11894-007-0005-417418056
- Federal Register. Docket No. 2003N-0205, Vol. 69, No. 2. Food and Drug Administration; 428, 2004.
- European Pharmacopeia, Monograph 0350, Pancreas Powder; 2020. Available from: https://www.edqm.eu/sites/default/files/medias/fichiers/European_Pharmacopoeia/The_European_Pharmacopoeia/European_Pharmacopoeia_10th_Edition/Index/european_pharmacopeia_supplement_10.2_english_index.pdfhttps://crs.edqm.eu/db/4DCGI/leaflet?leaflet=Y0001632_4. Accessed on 02 Sep 2021.
- USP43-NF38—page 3384, Current DocID: GUID-B713FD29-6584-4961-8C46-4A56F436AB85_1_en-US, Pancrelipase Delayed-Release Capsules; 2020. Available from: https://pdf.hres.ca/dpd_pm/00057600.PDF. Accessed on 02 Sep 2021
- LayerP, GrogerG, DickeD. Enzyme pellet size and luminal nutrient digestion in pancreatic insufficiency. Digestion. 1992;52:100–101.
- KuhneltP, MundlosS, AdlerG. [Effect of pellet size of a pancreas enzyme preparation on duodenal lipolytic activity]. Z Gastroenterol. 1991;29(9):417–421. German.1763562
- MeyerJH, ElashoffJ, Porter-FinkV, DressmanJ, AmidonGL. Human postprandial gastric emptying of 1-3-millimeter spheres. Gastroenterology. 1988;94(6):1315–1325. doi:10.1016/0016-5085(88)90669-53360258
- SteadRJ, SkypalaI, HodsonME, BattenJC. Enteric coated microspheres of pancreatin in the treatment of cystic fibrosis: comparison with a standard enteric coated preparation. Thorax. 1987;42(7):533–537. doi:10.1136/thx.42.7.5333326213
- NorregaardP, Lysgaard MadsenJ, LarsenS, WorningH. Gastric emptying of pancreatin granules and dietary lipids in pancreatic insufficiency. Aliment Pharmacol Ther. 1996;10(3):427–432. doi:10.1111/j.0953-0673.1996.00427.x8791973
- MundlosS, KuhneltP, AdlerG. Monitoring enzyme replacement treatment in exocrine pancreatic insufficiency using the cholesteryl octanoate breath test. Gut. 1990;31(11):1324–1328. doi:10.1136/gut.31.11.13242253920